Betting On Biosimilars In China? Think Again

Interchangeability, reimbursement, approval delays: as the issues keep piling up, will biosimilars offer attractive opportunities for pharma firms in China? Executives from front-running biotechs and legal experts shared their views at a recent meeting in Shanghai.